TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Natural Killer (NK) cells are crucial for controlling tumor metastasis and serve as prognostic markers in malignancies.
• Tumor cells often manipulate NK cell functions, thereby compromising their anti-tumor efficacy.

Purpose of the Study:

• To investigate the role of the TNFα/TNFR2/BIRC3/TRAF1 signaling cascade in NK cell function within the tumor microenvironment (TME).
• To elucidate the mechanisms by which tumor cells evade NK cell surveillance.

Main Methods:

• Analysis of TNFα-induced changes in NK cell gene expression, specifically NKp46/NCR1 and BIRC3/cIAP2.
• Assessment of NK cell surface receptor expression in the TME.
• Correlation of molecular findings with tumor metastasis in murine models and patient prognosis in GIST.

Main Results:

• Tumor necrosis factor-alpha (TNFα) upregulates BIRC3/cIAP2 and downregulates NKp46/NCR1 transcription and surface expression on NK cells.
• This TNFα-mediated pathway promotes tumor metastasis in mice and is associated with poor prognosis in gastrointestinal stromal tumor (GIST) patients.
• NKp30 engagement contributes to TNFα release and subsequent BIRC3 upregulation, particularly in patients with NKp30C isoforms.

Conclusions:

• The TNFα/TNFR2/BIRC3/TRAF1 axis represents a detrimental signaling pathway exploited by tumor cells to inhibit NK cell anti-tumor activity.
• In environments lacking IL-12 or a Th1 immune response, TNFα acts as a negative regulator of innate immune effectors like NK cells.
• Targeting this pathway could offer novel therapeutic strategies to enhance NK cell-mediated anti-cancer immunity.